4 Stocks That Keep On Coming Back Under Investors' Radar - BIT, NUH, MSB And OGX

The ASX is struggling around the 5700 mark and has yet again fallen below it. At the end of the week the markets closed flat amid the US president Trump’s meeting in Argentina. However, there are some stocks which continue to make it to the investor’s radar and perform better, four such stocks are as follows.

BIOTRON LIMITED (ASX:BIT) – The company in late November 2018 presentation of BIT225-009 HIV-1 phase 2 provides scientific data and analyses concerning the clinical trial. The results show that BIT225 has unique effects on patients. BIT225 targets and kills HIV?1 in macrophage cells even in people taking antiretroviral drugs as these are a key reservoir of infection which sets them apart. The company raised after costs $1.48 million via rights issue in June 2018. The principal place of Business is changed and is now located at Suite 3.3, 56 Delhi Road North Ryde, NSW. Underwriting agreement today as at November 30, 2018, $0.06 options in Oct ’18, will bring in $4.7 million. The stock price surged up by 14.815% as at November 30, 2018 to $0.155 and has witnessed a 380.08% change over the past twelve months. Â

NUHEARA LIMITED (ASX:NUH) – To provide hearing solutions to adults and children with mild to moderate hearing loss the company’s IQbuds BOOST™ has been selected by the United Kingdom’s (UK) National Health Service (NHS), via a formal tender process. The company has receipt of $1,940,741.19 as cash rebate from Australian Tax Office for R&D activities which represents a year-on-year increase of 60% for the previous period i.e. 2017 FY. Net cash inflows of $4,941,146 were attributable to $15,635,968 received through capital raisings, offset by $7,737,508 in net operating outflows, $122,337 for the purchase of plant and equipment and $4,043,428 for the purchase of intangible assets. Revenue from ordinary activities for the year was $5,251,960 which compared with revenue of $2,893,627 for the year ended 30 June 2016, i.e. growth of 80%. The stock price traded flat as at November 30, 2018 to $0.078, has witnessed a 34.48% change over the past twelve months.

MESOBLAST LIMITED (ASX:MSB) – The global cellular medicines company has well characterized mechanisms of action and the company is committed to bring to market disruptive cellular medicines to treat serious and life-threatening illnesses. Mesoblast is also eligible to receive €20 million in milestone payments plus royalties upon commercial sales of Alofisel worldwide. The company saw a substantial increase in revenue with first quarter FY2019 revenue increasing by US$10.5 million against the 2018 revenue. The total revenue as at September 30, 2018 is of $11.6 million as compared to September 30, 2017 of $1.2 million which is due to establishing a strategic cardiovascular partnership with Tasly in China. The stock price surged up by 0.76% as at November 30, 2018 to $1.325, has witnessed a -10.24% change over the past twelve months.

ORINOCO GOLD LIMITED (ASX:OGX) – For the Placement announced 20 November 2018 the Company has received and accepted a further $168,800 of late funds. It has placed 12,503,704 fully paid ordinary shares plus a free unlisted option on a 1 for one basis exercisable at 3 cents, expiring 21 September 2021. At a price of 1.35 cents each for new monies which represents a 22.67% discount to the 15-day VWAP (1.76 cents) before the agreed price is set the new shares will be allotted. The company has cash and cash equivalents for the period ending June 30, 2018 of $3,013,450 and has no debt facility on the balance sheet. The stock price is trading flat as at November 30, 2018 to $1.325 which is near its 52-week low, it has witnessed a -57.14% change over the past twelve months.

Disclaimer

This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.